Mobilizing potential of ifosfamide/vinorelbine-based chemotheraphy in pretreated malignant lymphoma

M. Magagnoli, B. Sarina, M. Balzarotti, L. Castagna, I. Timofeeva, A. Nozza, A. Bertuzzi, L. Siracusano, M. Sinnone, A. Santoro

Research output: Contribution to journalArticle

Abstract

The mobilizing potential and therapeutic activity of ifosfamide/vinorelbine-containing regimens with G-CSF support were explored in patients with pretreated malignant lymphomas. Ten patients with non-Hodgkin's lymphoma (NHL) received ifosfamide and vinorelbine, and 17 with Hodgkin's disease (HD) received ifosfamide, vinorelbine and gemcitabine (IGEV regimen), as induction chemotherapy before high-dose chemotherapy (HDT) with peripheral blood stem cell (PBSC) support. Most of the patients had been heavily pretreated with various chemotherapy regimens ± radiotherapy. The target yield was ≥3 × 106 CD34+ cells/kg of body weight in order to support the subsequent myeloablative chemotherapy. The optimal PBSC harvest occurred on days 11 and 12, with no difference in CD34+ cell mobilization kinetics between the ifosfamide/vinorelbine and IGEV regiments. The median number of CD34+ cells/kg body weight collected was 10.9 × 106 (range 1.76-61.1 × 106). The median total CD34+ cell/μ, CFU-GM and white blood cells (WBC) for all individual collections was 81.5/μ, 10 × 104/kg, and 17 900/μ, respectively. The target yield of CD34+ cells was reached in 24 of 27 patients. Hematological side-effects were acceptable and no treatment-related hospitalizations or toxic deaths occurred. Fifteen patients have so far received high-dose therapy and PBSC reinfusion with rapid engraftment. These results confirm that ifosfamide and vinorelbine-based chemotherapy regimen with G-CSF support can be successfully and safely used to mobilize PBSCs.

Original languageEnglish
Pages (from-to)923-927
Number of pages5
JournalBone Marrow Transplantation
Volume28
Issue number10
DOIs
Publication statusPublished - 2001

Fingerprint

Ifosfamide
Lymphoma
Drug Therapy
Granulocyte Colony-Stimulating Factor
gemcitabine
Body Weight
Granulocyte-Macrophage Progenitor Cells
Induction Chemotherapy
Poisons
Hodgkin Disease
Non-Hodgkin's Lymphoma
Hospitalization
Leukocytes
Radiotherapy
Therapeutics
vinorelbine
Peripheral Blood Stem Cells

Keywords

  • CD34 cells
  • Combination therapy
  • G-CSF
  • Malignant lymphoma
  • PBSC mobilization

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Mobilizing potential of ifosfamide/vinorelbine-based chemotheraphy in pretreated malignant lymphoma. / Magagnoli, M.; Sarina, B.; Balzarotti, M.; Castagna, L.; Timofeeva, I.; Nozza, A.; Bertuzzi, A.; Siracusano, L.; Sinnone, M.; Santoro, A.

In: Bone Marrow Transplantation, Vol. 28, No. 10, 2001, p. 923-927.

Research output: Contribution to journalArticle

@article{d4191e8868ea45149f758efe5c92a0a7,
title = "Mobilizing potential of ifosfamide/vinorelbine-based chemotheraphy in pretreated malignant lymphoma",
abstract = "The mobilizing potential and therapeutic activity of ifosfamide/vinorelbine-containing regimens with G-CSF support were explored in patients with pretreated malignant lymphomas. Ten patients with non-Hodgkin's lymphoma (NHL) received ifosfamide and vinorelbine, and 17 with Hodgkin's disease (HD) received ifosfamide, vinorelbine and gemcitabine (IGEV regimen), as induction chemotherapy before high-dose chemotherapy (HDT) with peripheral blood stem cell (PBSC) support. Most of the patients had been heavily pretreated with various chemotherapy regimens ± radiotherapy. The target yield was ≥3 × 106 CD34+ cells/kg of body weight in order to support the subsequent myeloablative chemotherapy. The optimal PBSC harvest occurred on days 11 and 12, with no difference in CD34+ cell mobilization kinetics between the ifosfamide/vinorelbine and IGEV regiments. The median number of CD34+ cells/kg body weight collected was 10.9 × 106 (range 1.76-61.1 × 106). The median total CD34+ cell/μ, CFU-GM and white blood cells (WBC) for all individual collections was 81.5/μ, 10 × 104/kg, and 17 900/μ, respectively. The target yield of CD34+ cells was reached in 24 of 27 patients. Hematological side-effects were acceptable and no treatment-related hospitalizations or toxic deaths occurred. Fifteen patients have so far received high-dose therapy and PBSC reinfusion with rapid engraftment. These results confirm that ifosfamide and vinorelbine-based chemotherapy regimen with G-CSF support can be successfully and safely used to mobilize PBSCs.",
keywords = "CD34 cells, Combination therapy, G-CSF, Malignant lymphoma, PBSC mobilization",
author = "M. Magagnoli and B. Sarina and M. Balzarotti and L. Castagna and I. Timofeeva and A. Nozza and A. Bertuzzi and L. Siracusano and M. Sinnone and A. Santoro",
year = "2001",
doi = "10.1038/sj.bmt.1703265",
language = "English",
volume = "28",
pages = "923--927",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Mobilizing potential of ifosfamide/vinorelbine-based chemotheraphy in pretreated malignant lymphoma

AU - Magagnoli, M.

AU - Sarina, B.

AU - Balzarotti, M.

AU - Castagna, L.

AU - Timofeeva, I.

AU - Nozza, A.

AU - Bertuzzi, A.

AU - Siracusano, L.

AU - Sinnone, M.

AU - Santoro, A.

PY - 2001

Y1 - 2001

N2 - The mobilizing potential and therapeutic activity of ifosfamide/vinorelbine-containing regimens with G-CSF support were explored in patients with pretreated malignant lymphomas. Ten patients with non-Hodgkin's lymphoma (NHL) received ifosfamide and vinorelbine, and 17 with Hodgkin's disease (HD) received ifosfamide, vinorelbine and gemcitabine (IGEV regimen), as induction chemotherapy before high-dose chemotherapy (HDT) with peripheral blood stem cell (PBSC) support. Most of the patients had been heavily pretreated with various chemotherapy regimens ± radiotherapy. The target yield was ≥3 × 106 CD34+ cells/kg of body weight in order to support the subsequent myeloablative chemotherapy. The optimal PBSC harvest occurred on days 11 and 12, with no difference in CD34+ cell mobilization kinetics between the ifosfamide/vinorelbine and IGEV regiments. The median number of CD34+ cells/kg body weight collected was 10.9 × 106 (range 1.76-61.1 × 106). The median total CD34+ cell/μ, CFU-GM and white blood cells (WBC) for all individual collections was 81.5/μ, 10 × 104/kg, and 17 900/μ, respectively. The target yield of CD34+ cells was reached in 24 of 27 patients. Hematological side-effects were acceptable and no treatment-related hospitalizations or toxic deaths occurred. Fifteen patients have so far received high-dose therapy and PBSC reinfusion with rapid engraftment. These results confirm that ifosfamide and vinorelbine-based chemotherapy regimen with G-CSF support can be successfully and safely used to mobilize PBSCs.

AB - The mobilizing potential and therapeutic activity of ifosfamide/vinorelbine-containing regimens with G-CSF support were explored in patients with pretreated malignant lymphomas. Ten patients with non-Hodgkin's lymphoma (NHL) received ifosfamide and vinorelbine, and 17 with Hodgkin's disease (HD) received ifosfamide, vinorelbine and gemcitabine (IGEV regimen), as induction chemotherapy before high-dose chemotherapy (HDT) with peripheral blood stem cell (PBSC) support. Most of the patients had been heavily pretreated with various chemotherapy regimens ± radiotherapy. The target yield was ≥3 × 106 CD34+ cells/kg of body weight in order to support the subsequent myeloablative chemotherapy. The optimal PBSC harvest occurred on days 11 and 12, with no difference in CD34+ cell mobilization kinetics between the ifosfamide/vinorelbine and IGEV regiments. The median number of CD34+ cells/kg body weight collected was 10.9 × 106 (range 1.76-61.1 × 106). The median total CD34+ cell/μ, CFU-GM and white blood cells (WBC) for all individual collections was 81.5/μ, 10 × 104/kg, and 17 900/μ, respectively. The target yield of CD34+ cells was reached in 24 of 27 patients. Hematological side-effects were acceptable and no treatment-related hospitalizations or toxic deaths occurred. Fifteen patients have so far received high-dose therapy and PBSC reinfusion with rapid engraftment. These results confirm that ifosfamide and vinorelbine-based chemotherapy regimen with G-CSF support can be successfully and safely used to mobilize PBSCs.

KW - CD34 cells

KW - Combination therapy

KW - G-CSF

KW - Malignant lymphoma

KW - PBSC mobilization

UR - http://www.scopus.com/inward/record.url?scp=0035195161&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035195161&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1703265

DO - 10.1038/sj.bmt.1703265

M3 - Article

C2 - 11753545

AN - SCOPUS:0035195161

VL - 28

SP - 923

EP - 927

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 10

ER -